Organogenesis Holdings Inc (NASDAQ:ORGO) shares, rose in value, with the stock price up by 0.35% to the previous day’s close as strong demand from buyers drove the stock to $2.85.
Actively observing the price movement in the last trading, the stock closed the session at $2.84. The value of beta (5-year monthly) was 1.58 whereas the PE ratio was 77.66 over 12-month period. Referring to stock’s 52-week performance, its high was $4.70, and the low was $1.79. On the whole, ORGO has fluctuated by -22.45% over the past month.
With the market capitalization of Organogenesis Holdings Inc currently standing at about $376.09 million, investors are eagerly awaiting this quarter’s results, scheduled for May 08, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.03, which is expected to increase to $0.01 for fiscal year -$0.01 and then to about $0.06 by fiscal year 2025. Data indicates that the EPS growth is expected to be -125.00% in 2025, while the next year’s EPS growth is forecast to be 700.00%.
Analysts have estimated the company’s revenue for the quarter at $101.05 million, with a low estimate of $100.2 million and a high estimate of $101.9 million. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $454.69 million, representing an increase of 5.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ORGO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 32.22, with the price of ORGO currently trading nearly -11.52% and -19.01% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.91, while the 7-day volatility ratio is showing 5.95% which for the 30-day chart, stands at 7.37%. Furthermore, Organogenesis Holdings Inc (ORGO)’s beta value is 1.58, and its average true range (ATR) is 0.23.
A comparison of Organogenesis Holdings Inc (ORGO) with its peers suggests the former has fared considerably weaker in the market. ORGO showed an intraday change of 0.35% in last session, and over the past year, it grew by 31.94%%.
Data on historical trading for Organogenesis Holdings Inc (NASDAQ:ORGO) indicates that the trading volumes over the past 10 days have averaged 1.0 million and over the past 3 months, they’ve averaged 726.48K. According to company’s latest data on outstanding shares, there are 131.32 million shares outstanding.
Nearly 41.30% of Organogenesis Holdings Inc’s shares belong to company insiders and institutional investors own 44.41% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 7.57 million shares as on Feb 29, 2024, resulting in a short ratio of 15.33. According to the data, the short interest in Organogenesis Holdings Inc (ORGO) stood at 5.73% of shares outstanding as of Feb 29, 2024; the number of short shares registered in Jan 31, 2024 reached 6.71 million. The stock has fallen by -30.32% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ORGO stock heading into the next quarter.
